Cargando…
A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19
OBJECTIVE: To describe the process and outcome of creating a patient cohort in the early stages of the COVID-19 pandemic in order to better understand the process of and predict the outcomes of COVID-19. PATIENTS AND METHODS: A total of 1169 adults aged 18 years of age or older who tested positive i...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053748/ https://www.ncbi.nlm.nih.gov/pubmed/33855875 http://dx.doi.org/10.1177/21501327211010991 |
_version_ | 1783680178984058880 |
---|---|
author | Nanda, Sanjeev Toussaint, Loren Vincent, Ann Fischer, Karen M. Hurt, Ryan Schroeder, Darrell R. Chacin Suarez, Audry S. Medina Inojosa, Jose R. O’Horo, John C. DeJesus, Ramona S. Abu Lebdeh, Haitham S. Mundi, Manpreet S. Iftikhar, Salma Croghan, Ivana T. |
author_facet | Nanda, Sanjeev Toussaint, Loren Vincent, Ann Fischer, Karen M. Hurt, Ryan Schroeder, Darrell R. Chacin Suarez, Audry S. Medina Inojosa, Jose R. O’Horo, John C. DeJesus, Ramona S. Abu Lebdeh, Haitham S. Mundi, Manpreet S. Iftikhar, Salma Croghan, Ivana T. |
author_sort | Nanda, Sanjeev |
collection | PubMed |
description | OBJECTIVE: To describe the process and outcome of creating a patient cohort in the early stages of the COVID-19 pandemic in order to better understand the process of and predict the outcomes of COVID-19. PATIENTS AND METHODS: A total of 1169 adults aged 18 years of age or older who tested positive in Mayo Clinic Rochester or the Mayo Clinic Midwest Health System between January 1 and May 23 of 2020. RESULTS: Patients were on average 43.9 years of age and 50.7% were female. Most patients were white (69.0%), and Blacks (23.4%) and Asians (5.8%) were also represented in larger numbers. Hispanics represented 16.3% of the sample. Just under half of patients were married (48.4%). Common comorbid conditions included: cardiovascular diseases (25.1%), dyslipidemia (16.0%), diabetes mellitus (11.2%), chronic obstructive pulmonary disease (6.6%), asthma (7.5%), and cancer (5.1%). All other comorbid conditions were less the 5% in prevalence. Data on 3 comorbidity indices are also available including the: DHHS multi-morbidity score, Charlson Comorbidity Index, and Mayo Clinic COVID-19 Risk Factor Score. CONCLUSION: In addition to managing the ever raging pandemic and growing death rates, it is equally important that we develop adequate resources for the investigation and understanding of COVID-19-related predictors and outcomes. |
format | Online Article Text |
id | pubmed-8053748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-80537482021-05-03 A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19 Nanda, Sanjeev Toussaint, Loren Vincent, Ann Fischer, Karen M. Hurt, Ryan Schroeder, Darrell R. Chacin Suarez, Audry S. Medina Inojosa, Jose R. O’Horo, John C. DeJesus, Ramona S. Abu Lebdeh, Haitham S. Mundi, Manpreet S. Iftikhar, Salma Croghan, Ivana T. J Prim Care Community Health Pilot Studies OBJECTIVE: To describe the process and outcome of creating a patient cohort in the early stages of the COVID-19 pandemic in order to better understand the process of and predict the outcomes of COVID-19. PATIENTS AND METHODS: A total of 1169 adults aged 18 years of age or older who tested positive in Mayo Clinic Rochester or the Mayo Clinic Midwest Health System between January 1 and May 23 of 2020. RESULTS: Patients were on average 43.9 years of age and 50.7% were female. Most patients were white (69.0%), and Blacks (23.4%) and Asians (5.8%) were also represented in larger numbers. Hispanics represented 16.3% of the sample. Just under half of patients were married (48.4%). Common comorbid conditions included: cardiovascular diseases (25.1%), dyslipidemia (16.0%), diabetes mellitus (11.2%), chronic obstructive pulmonary disease (6.6%), asthma (7.5%), and cancer (5.1%). All other comorbid conditions were less the 5% in prevalence. Data on 3 comorbidity indices are also available including the: DHHS multi-morbidity score, Charlson Comorbidity Index, and Mayo Clinic COVID-19 Risk Factor Score. CONCLUSION: In addition to managing the ever raging pandemic and growing death rates, it is equally important that we develop adequate resources for the investigation and understanding of COVID-19-related predictors and outcomes. SAGE Publications 2021-04-15 /pmc/articles/PMC8053748/ /pubmed/33855875 http://dx.doi.org/10.1177/21501327211010991 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Pilot Studies Nanda, Sanjeev Toussaint, Loren Vincent, Ann Fischer, Karen M. Hurt, Ryan Schroeder, Darrell R. Chacin Suarez, Audry S. Medina Inojosa, Jose R. O’Horo, John C. DeJesus, Ramona S. Abu Lebdeh, Haitham S. Mundi, Manpreet S. Iftikhar, Salma Croghan, Ivana T. A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19 |
title | A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19 |
title_full | A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19 |
title_fullStr | A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19 |
title_full_unstemmed | A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19 |
title_short | A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19 |
title_sort | midwest covid-19 cohort for the evaluation of multimorbidity and adverse outcomes from covid-19 |
topic | Pilot Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053748/ https://www.ncbi.nlm.nih.gov/pubmed/33855875 http://dx.doi.org/10.1177/21501327211010991 |
work_keys_str_mv | AT nandasanjeev amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT toussaintloren amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT vincentann amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT fischerkarenm amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT hurtryan amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT schroederdarrellr amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT chacinsuarezaudrys amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT medinainojosajoser amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT ohorojohnc amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT dejesusramonas amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT abulebdehhaithams amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT mundimanpreets amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT iftikharsalma amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT croghanivanat amidwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT nandasanjeev midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT toussaintloren midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT vincentann midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT fischerkarenm midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT hurtryan midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT schroederdarrellr midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT chacinsuarezaudrys midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT medinainojosajoser midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT ohorojohnc midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT dejesusramonas midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT abulebdehhaithams midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT mundimanpreets midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT iftikharsalma midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 AT croghanivanat midwestcovid19cohortfortheevaluationofmultimorbidityandadverseoutcomesfromcovid19 |